Low molecular weight heparin for hickman catheter-induced thrombosis in thrombocytopenic patients undergoing bone marrow transplantation
Open Access
- 1 October 1992
- Vol. 70 (7), 1895-1898
- https://doi.org/10.1002/1097-0142(19921001)70:7<1895::aid-cncr2820700715>3.0.co;2-i
Abstract
Background. Patients with an indwelling central venous catheter are prone to development of thrombotic complications. Thrombocytopenia in patients undergoing bone marrow transplantation (BMT) generally is protracted. The management of thrombosis in thrombocytopenic patients is difficult because heparin and warfarin are relatively contraindicated because of the high risk of major bleeding. Low molecular weight heparin (LMWH) is a new class of antithrombotic drug. Enoxaparin (Rhone Poulenc Rorer, Antony, France) is an LMWH that has been shown to be effective in the treatment and prophylaxis of venous thrombosis. Enoxaparin, with its high antithrombotic to anticoagulant ratio, may be safer than standard heparin in patients at high risk of hemorrhagic complications. Methods. The authors report the cases of five thrombocytopenic patients, undergoing autologous BMT, in whom venous thrombosis developed related to a Hickman catheter. Results. All the patients were treated with Enoxaparin and recovered promptly without hemorrhagic complications. Conclusions. The authors suggest that Enoxaparin is an effective drug in treating thrombocytopenic patients in whom acute venous thrombosis develops. Cancer 1992; 70:1895–1898.Keywords
This publication has 14 references indexed in Scilit:
- Low molecular weight heparinBlood, 1992
- HeparinNew England Journal of Medicine, 1991
- Hickman catheter-induced thoracic vein thrombosis. Frequency and long-term sequelae in patients receiving high-dose chemotherapy and marrow transplantationCancer, 1990
- Complications of central venous cannulation.BMJ, 1988
- A Randomized Controlled Trial of a Low-Molecular-Weight Heparin (Enoxaparin) to Prevent Deep-Vein Thrombosis in Patients Undergoing Elective Hip SurgeryNew England Journal of Medicine, 1986
- Heparin-induced ThrombocytopeniaChest, 1985
- Treatment of Heparin-Associated Thrombocytopenia and Thrombosis with Low Molecular Weight Heparin (CY 216)Seminars in Thrombosis and Hemostasis, 1985
- Heparin-Associated ThrombocytopeniaAnnals of Internal Medicine, 1984
- Occlusion and infection in broviac catheters during intensive cancer therapyCancer, 1983
- The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombinBiochemical Journal, 1981